Targeting Jun N-terminal kinase phosphorylation: A human-derived hepatoprotective peptide human liver transplantation peptide 1 attenuates hepatic ischemia-reperfusion injury

Figure 5 RNA-seq analysis indicate that human liver transplantation peptide 1 is involved in the mitogen-activated protein kinases pathway. A: The heat map of significant differences genes; B: This volcano plot represents the distribution of significant differences genes; C: Kyoto Encyclopedia of Genes and Genomes analysis; D: Randomized controlled trial analysis of interleukin-17 signaling pathway; E: Protein levels of Jun N-terminal kinase and phosphorylated-Jun N-terminal kinase in hypoxia/reoxygenation treated AML12 cells with human liver transplantation peptide 1 (0 μM, 1 μM, 3 μM, 10 μM, 30 μM); F: 3D interaction diagram of human liver transplantation peptide 1 with Jun N-terminal kinase. H/R: Hypoxia/reoxygenation; HLTP1: Human liver transplantation peptide 1; IL-17: Interleukin-17; TNF: Tumor necrosis factor; JNK: Jun N-terminal kinase; p-JNK: Phosphorylated-Jun N-terminal kinase. ^bP < 0.01, and ^cP < 0.001.